Glutathione is a tripeptide — three amino acids, glutamate, cysteine and glycine — made in every cell. It is sold by clinics, med-spas and compounding pharmacies as an intramuscular shot or an IV drip. This page takes the benefits those businesses list and sets each one beside the trials that actually gave glutathione by injection or infusion.
What the molecule is, in plain terms, is in Peptide Lexicon's glutathione entry. The harms side — including FDA's 2026 alert on contaminated compounded vials — is on our glutathione injection side effects page, the absorption question is on our injection vs oral comparison, and the doses trials and clinics use are on our glutathione dosage page. Nothing here is a recommendation.
The claims, as the search results state them
On 20 October 2026, Google's AI Overview for "glutathione injection benefits" listed five benefits: antioxidant and cellular protection, skin brightening and tone, liver detoxification, immune support, and reduced inflammation. It sourced them to a wellness centre, an IV-therapy business, a medical spa, two compounding pharmacies and a medical-dental clinic, plus one PubMed Central review on skin lightening. The organic results below it were mostly the same kind of page; WebMD's supplement entry and the same PubMed Central review were the only non-commercial results on page one.
None of those five claims names a disease, a dose or a measured outcome. Trials do. So the useful question is not "is glutathione an antioxidant" — it is — but whether injecting it has changed anything measurable in people.
The record, claim by claim
| Claim on clinic pages | Controlled human trial of injected or infused glutathione | What it measured | Result |
|---|---|---|---|
| Antioxidant / cellular protection | Tanzilli 2019, 50 heart-attack patients before angioplasty | Hydrogen-peroxide markers, troponin | Oxidative markers lower; no clinical outcome measured |
| Nerve protection (not advertised, but the best-tested use) | Cascinu 1995 (50) and 2002 (52); Leal 2014 (185 analysed) | Chemotherapy nerve damage | Positive in the two Italian trials; null in the larger US trial |
| Brain / neurological | Hauser 2009, 21 people with Parkinson's disease | Disease-rating score | No significant difference from placebo |
| Circulation | Arosio 2002, 40 people with leg artery disease, 5 days | Pain-free walking distance | 196 m vs 143 m |
| Liver detoxification | Zhang 2000, 110 people with alcoholic liver disease | Liver enzymes vs another liver drug | No difference between arms; no placebo |
| Immune support | None located | — | — |
| Skin brightening | No adequately powered trial; reviewed below | Skin tone | Modest, inconsistent |
| Mood | Eshkevari 2024, 30 people on ketamine for depression | Depression scores | No difference from saline |
| Fertility | Lenzi 1993, 20 men, intramuscular, crossover | Sperm motility and shape | Improved on glutathione |
Sources: PMIDs 31399448, 7799029, 12177109, 24619793, 19230029, 12173710, 10951629, 38795698, 8300824, abstracts read 20 October 2026.
How the census was done
The table comes from one PubMed query run on 20 October 2026: glutathione in the title, a route word (intravenous, infusion, intramuscular, injection or parenteral) in the title or abstract, and the publication type "randomized controlled trial". It returned 42 records. Most were not tests of glutathione as a treatment at all: they measured glutathione levels as a marker while testing something else (glutamine, whey protein, cysteine, anaesthetic drugs). The trials in the table are the ones that gave glutathione itself and measured a clinical or functional result. The query can be re-run by anyone; a search engine's "related" results will differ.
Chemotherapy nerve damage: the best-tested use, and a split result
The use with the most rigorous testing is not one clinics advertise. Platinum chemotherapy drugs damage nerves in the hands and feet, and glutathione was tried as a shield.
- Cisplatin, 1995. Fifty people with advanced gastric cancer received glutathione 1.5 g/m² infused over 15 minutes before each weekly dose, then 600 mg by intramuscular injection on days two to five, or saline. After 15 weeks, 4 of 24 assessable patients on glutathione had nerve damage against 16 of 18 on placebo. Tumour response was not reduced.
- Oxaliplatin, 2002. Fifty-two people with advanced colorectal cancer, same infusion dose. After 12 cycles, grade 2–4 nerve damage was seen in 3 patients on glutathione against 8 on placebo.
- Paclitaxel and carboplatin, 2014. The US Alliance trial N08CA gave 1.5 g/m² before chemotherapy to women with ovarian, fallopian-tube or peritoneal cancer. ClinicalTrials.gov (NCT02311907, read 20 October 2026) lists 195 enrolled; the paper analysed 185 (94 glutathione, 91 placebo). There was no statistically significant difference in nerve damage on either rating scale, and two measures favoured placebo: time to grade 2 or worse neuropathy (p = 0.039), and paclitaxel's acute pain syndrome in women on weekly paclitaxel (p = 0.002). The authors wrote that the results "do not support the use of glutathione".
The two positive trials were small Italian studies of about 50 patients each, with platinum drugs alone; the null trial was larger, multi-centre and added paclitaxel, which damages nerves by a different mechanism. ASCO's 2020 guideline update on chemotherapy neuropathy (Loprinzi et al., PMID 32663120) reconfirmed that no agent is recommended to prevent it. A benefit in this one setting would say nothing, in any case, about a wellness drip in a healthy adult.
Parkinson's disease: the claim that circulates most, tested once
Intravenous glutathione for Parkinson's disease was promoted in the US for years before it was tested blind. The test came in 2009: 21 people whose symptoms were not controlled by their medicines received 1,400 mg intravenously three times a week for four weeks, or placebo. It was well tolerated. The disease-rating score improved by 2.8 points more on glutathione during treatment (p = 0.32, not significant) and worsened by 3.5 points more over the following eight weeks (p = 0.54). The authors called it a possible mild symptomatic effect that needed a larger study. A larger study of the intravenous form was not found in the census.
Circulation and the heart
Forty Italians with stage II leg artery disease (pain on walking) received intravenous glutathione or saline twice a day for five days. Pain-free walking distance was 196 m against 143 m at the end, with better blood-flow readings — a short trial, measured 12 hours after the last infusion, with no follow-up beyond that.
In heart attack, a 50-patient Italian pilot infused 2,500 mg before emergency angioplasty and again at 24, 48 and 72 hours. Markers of oxidative stress were lower and tracked with troponin, a heart-damage marker; no clinical outcome such as death or heart failure was measured, and the authors pointed to a larger trial as the confirmation. That is the closest the record comes to the "antioxidant protection" claim: a change in chemistry in a hospital emergency.
Liver "detox"
No trial located measured detoxification — removal of toxins or heavy metals — after a glutathione injection. The liver trials are disease trials. The one randomised trial in the census, from China in 2000, gave 110 people with alcoholic liver disease a daily glutathione infusion for 30 days or another liver drug by the same route. Enzymes and bilirubin improved in both arms, with no significant difference between them (efficacy rate 93% vs 96%). There was no placebo arm, so the improvement cannot be separated from stopping drinking or time.
Skin brightening
The skin claim gets the most marketing and some of the thinnest trials. A 2026 narrative review (Aloraini et al., PMID 42751591) searched four databases to March 2026 and found "limited evidence of modest, varied" pigmentation changes, small samples, unstandardised outcomes and short follow-up — and noted that vitamin C is so routinely given at the same time that the independent effect of glutathione is hard to know. It concluded the evidence is "too limited to justify routine use". The often-cited "safe and effective" parenteral study from King Saud University (PMID 31885127) was in guinea pigs. The full skin record, including topical and oral forms, is PeptideGlowJournal's glutathione for skin page.
Immune support, energy and the rest
No randomised trial in the census gave injected glutathione and measured immune function, infection rates, energy, fatigue or ageing in healthy people. The other trials found were small and disease-specific: ten people with type 2 diabetes given a one-hour infusion during a glucose clamp in 1998 (glucose uptake rose slightly), and 20 dialysis patients given glutathione for 120 days in 1992 (haemoglobin rose, then fell back to baseline when treatment stopped). In the 2024 depression trial, 30 people having ketamine infusions improved equally whether glutathione or saline was added.
What the record does not contain
- A trial of injected glutathione for detoxification, immunity, energy, weight or anti-ageing in healthy adults.
- An adequately powered skin-lightening trial with glutathione given alone.
- A trial comparing intravenous with intramuscular glutathione.
- An approved glutathione injection in the United States. Compounded vials are made from bulk powder; FDA's 2019 and 2026 warnings about supplement-grade powder are on our side effects page.
The same question for the other drip sold in these clinics is answered in our claim-by-claim check of NAD+ drips. A clinician who knows a person's medicines and conditions is the one to weigh any of this for an individual.
Sources and dates
Read 20 October 2026: Google results and AI Overview for "glutathione injection benefits" (US, desktop); PubMed query described above (42 records) and abstracts of PMIDs 7799029, 12177109, 24619793, 32663120, 19230029, 12173710, 31399448, 10951629, 38795698, 8300824, 1501736, 9711998, 42751591 and 31885127; ClinicalTrials.gov record NCT02311907.